Pelthos Therapeutics Inc. · AMEX:PTHS
Pelthos Therapeutics — Channel Therapeutics — Merger or Acquisition (April 2025)
27 slides from Pelthos Therapeutics's merger presentation, Apr 17, 2025
Slide 1: Pelthos Therapeutics Corporate Presentation Q2 2025
OT Pelthos Therapeuties Corporate Corporate Presentation Presentation Q 2 2 0 2 5 SO) NSD) NaN CONFIDENTIAL 1
Slide 2: Disclaimers
Disclaimers Important Information for Investors This confidential presentation (“Presentation”) is for informational purposes only and is being provided to interested parties solely in their capacity as potential investors for the purpose of evaluating a potential private offering of securities (the
Slide 3: Disclaimers (cont.)
Disclaimers (cont.) Private Placement This Presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities of CHRO or LNHC, nor does it constitute an offer to sell or a solicitation of an offer to buy any securities from any person in any state or other jurisd
Slide 4: Risk Factors
Risk Factors Both CHRO and LNHC are subject to various risks associated with their businesses and their industries. In addition, the Proposed Transaction, including the possibility that the Proposed Transaction may not be completed, poses a number of risks to each company and its respective security
Slide 5: Merger of Pelthos Therapeutics and Channel Therapeutics (1/2)
Merger of Pelthos Therapeutics and Channel Therapeutics (1/2) Creates commercial stage therapeutics company focused on infectious skin diseases • Pelthos Therapeutics Inc./LNHC (“Pelthos”), wholly owned subsidiaries of Ligand Pharmaceuticals, intend to merge with Channel Therapeutics, Inc. (NYSE Ame
Slide 6: Merger of Pelthos Therapeutics and Channel Therapeutics (2/2)
Merger of Pelthos Therapeutics and Channel Therapeutics (2/2) Creates commercial stage therapeutics company focused on infectious skin diseases • To fund the pre-launch and commercialization activities for ZelsuvmiTM, expected to launch in mid-2025, the lead PIPE investors provided $12.1 million in
Slide 7: Introduction to Pelthos Therapeutics
Introduction to Pelthos Therapeutics Scalable biopharmaceutical company with an FDA approved product with launch targeted in mid-2025 Company Overview • Pelthos is a biopharmaceutical company with a validated, novel, nitric oxide technology platform, primarily focused on commercializing innovative t
Slide 8: Nitricil is Pelthos' Proprietary Nitric Oxide-Based Technology Platform
Nitricil is Pelthos’ Clinically Proven Proprietary Nitric OxideBased Technology Platform Nitric Oxide Overview NitricilTM ✓ Stable storage1 − Druggable form of nitric oxide with shelf-life stability ✓ Therapeutic Berdazimer Sodium • • quantities1 New Chemical Entity (NCE) − High loading capacity ✓ T
Slide 9: Zelsuvmi
OT Pelthos Therapeutics TM Zelsuvmi Zelsuvmi™™ CONFIDENTIAL 9
Slide 10: Molluscum Contagiosum
Molluscum Contagiosum A highly infectious viral condition primarily affecting children 1 year of age or older Point prevalence of 3-6 million children (ages 0-16) in the U.S. Molluscum Contagiosum is caused by a pox virus and is characterized by small, round, firm, umbilicated, often painless bumps.
Slide 11: Zelsuvmi Is the First and Only At-Home Treatment for MC
Zelsuvmi Is the First and Only At-Home Treatment for MC That Offers a First-Line Efficacious and Safe Treatment Option Zelsuvmi Vision Zelsuvmi is the first and only at-home treatment that could revolutionize how MC is treated today for patients greater than 1 year old FDA-approved treatment for MC
Slide 12: Zelsuvmi Has the Potential to Shift MC Treatment Paradigm
Zelsuvmi Has the Potential to Shift MC Treatment Paradigm Current Options Zelsuvmi • Other available topical treatment requires in-office visits every 3 weeks2 • Painful, destructive treatments3 • Necessitates travel to HCP offices, adding to the time burden for MC patients and caregivers2 • Remaini
Slide 13: Zelsuvmi Is Easy to Apply and Can be Administered at Home
Zelsuvmi Is Easy to Apply and Can be Administered at Home Packaging Overview Application Overview Zelsuvmi (berdazimer) topical gel, 10.3% is supplied in a carton containing two tubes (NDC 83787-103-31) Gel containing berdazimer sodium Hydrogel that promotes nitric oxide release Tube A (14 g) with b
Slide 14: Zelsuvmi Efficacy Shown in Phase 3 Clinical Trials
Zelsuvmi Efficacy Shown in Phase 3 Clinical Trials Population Intervention Key Study Highlights 808 Males, 790 Females 1,598 participants randomized Immunocompetent children and adults aged ≥6 months with 3-70 raised MC lesions Mean age: 6.7 years (Range: 0.9 – 76.6 years) B-SIMPLE4 Study Locations
Slide 15: Phase 3 Trials: Benefit vs. Vehicle After 2 Weeks
Phase 3 Trials Zelsuvmi showed statistically significant benefit vs. vehicle after 2 weeks of therapy and throughout the entire 12-week length of the Phase 3 studies Least Squares Mean Lesion Reduction(1) Baseline Week 2 Week 4 0.0% Week 8 Week 12 Baseline Week 2 Week 4 0.0% -1.1% -10.7% Median Lesi
Slide 16: B-SIMPLE4 Phase 3 Trial
B-SIMPLE4 Phase 3 Trial Complete clearance is hard to achieve due to the nature of molluscum and similar dermatological conditions Percentage of Subjects With Complete Clearance of Treatable Lesions Primary Efficacy Endpoint at Week 12 “…an exit interview revealed that 23 of 30 patients or caregiver
Slide 17: B-SIMPLE4 Phase 3 Trial (cont.)
B-SIMPLE4 Phase 3 Trial (cont.) Zelsuvmi Zelsuvmi showed significant benefit over vehicle, including 43.5% of patients administered having zero or one remaining lesions after 12 weeks Secondary Endpoints 90% Clearance at Week 12 0 or 1 Remaining Lesions at Week 12 43.50%**** 43.00%**** 24.60% 23.90%
Slide 18: Key Leverage Points to Maximize Commercial Potential of Zelsuvmi
Activating Key Leverage Points Is Essential to Maximize the Commercial Potential of Zelsuvmi Key Leverage Points Addressable Patient Population Treated Patients Adherence Price and Revenue CONFIDENTIAL 01 Driving efficient disease awareness and patient presentation to physicians will be critical to
Slide 19: Zelsuvmi is a Breakthrough Product
Zelsuvmi is a Breakthrough Product “When this becomes available, it will be a gamechanger in treating molluscum.” -Dermatologist “There is nothing else like it for molluscum. It works differently than destruction.” -Dermatologist “Finally, I will be able to send the mom home with something instead o
Slide 20: Channel Therapeutics' Pipeline Programs
OT Pelthos Therapeutics Channel Channel Therapeutics’ Therapeutics’ Pipeline Pipeline Programs Programs CONFIDENTIAL 20
Slide 21: Sodium Channels (NaVs) and Pain Perception
Sodium Channels (NaVs) and Pain Pain Perception Sodium channels play a crucial role in pain transmission. • Action potentials are the electrical waves that the body uses to send information through nerves. − These action potentials are created through fluxes of various ions, including sodium ions, a
Slide 22: Why NaV1.7 is a Good Target for Pain Treatment
Why NaV1.7 is a Good Target for Pain Treatment Genetic validation suggests NaV1.7 suppression is an attractive pharmacological target for pain management Congenital Insensitivity to Pain Spectrum of NaV1.7 Activity Severe Pain Congenital Insensitivity to Pain Severe Pain Lack of NaV1.7 (Rare conditi
Slide 23: CC8464 (Neuropathic Pain) – Development Status
CC8464 (Neuropathic Pain) – Development Status Preclinical • Potent inhibitor of human NaV1.7; Subtype selective • Demonstrated in vivo efficacy in several rodent models of pain: Acute, chronic neuropathic, inflammatory, visceral and post-surgical • No CNS and muscle/motor dysfunction effects Chemis
Slide 24: Depot Treatment Program Plan
Depot Treatment Program Plan Strategy • Four novel depot and one novel injectable formulations of CC8464 have been created. The intent is to use these to allow for nerve blocks for post-operative pain for several days after surgery (e.g. shoulder surgery, knee surgery). • Animal efficacy and PK stud
Slide 25: Eye Pain
Eye Pain Eye pain is common with both acute and chronic etiologies that include: Corneal Induced Chronic Pain from Dry Eye/LASIK, Post Photorefractive keratectomy (PRK) surgery, second eye cataract surgery, acute corneal abrasion, Ectropion/ Entropion, Acute closed angle glaucoma, Uveitis, Iritis/Sc
Slide 26: Eye Pain Treatment Program Plan – CT2000
Eye Pain Treatment Program Plan – CT2000 Strategy • Conduct ocular safety test in rabbits – completed. Showed that up to 20mg/mL eye drops were safe (GLP chronic tox and ocular irritation studies all clean) • Conduct ocular efficacy in acute and chronic animal models – completed. Showing fast onset
Slide 27: Key Highlights
Key Highlights FDA Approved Product CONFIDENTIAL In January 2024, the FDA approved Zelsuvmi as the first and only at-home treatment aimed to revolutionize how MC is treated today for patients ≥ 1 year old Significant Unmet Need and Sizeable Market Opportunity Molluscum contagiosum is a highly contag
Channel Therapeutics — Merger or Acquisition (April 2025) on 6ix